Advances in chemotherapy for HER2-negative metastatic breast cancer

被引:3
|
作者
Mukai, Hirofumi [1 ]
Ito, Mayuko [1 ]
机构
[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
关键词
Breast cancer; chemotherapy; quality of life (QOL); survival;
D O I
10.21037/cco.2018.06.01
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
  • [2] When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    Miles, David W.
    BREAST CANCER RESEARCH, 2009, 11 (04)
  • [3] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [4] Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
    Wan, Guoxing
    Cao, Fengjun
    Wang, Xuanbin
    Sun, Xue
    JOURNAL OF CANCER, 2019, 10 (02): : 416 - 417
  • [5] New Advances in Targeted Therapy of HER2-Negative Breast Cancer
    An, Junsha
    Peng, Cheng
    Xie, Xiaofang
    Peng, Fu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [7] Current approaches to the management of Her2-negative metastatic breast cancer
    Gogineni, Keerthi
    DeMichele, Angela
    BREAST CANCER RESEARCH, 2012, 14 (02)
  • [8] Bevacizumab in HER2-negative non-metastatic breast cancer
    Bennet, Neil
    LANCET ONCOLOGY, 2012, 13 (03): : E93 - E93
  • [9] Current approaches to the management of Her2-negative metastatic breast cancer
    Keerthi Gogineni
    Angela DeMichele
    Breast Cancer Research, 14
  • [10] Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    David W Miles
    Breast Cancer Research, 11